These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 29346605)

  • 21. Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial.
    Tsimberidou AM; Braiteh F; Stewart DJ; Kurzrock R
    J Clin Oncol; 2009 Dec; 27(36):6243-50. PubMed ID: 19826112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accelerated approval dust begins to settle.
    Mullard A
    Nat Rev Drug Discov; 2011 Oct; 10(11):797-8. PubMed ID: 22037027
    [No Abstract]   [Full Text] [Related]  

  • 23. The Food and Drug Administration's early access and fast-track approval initiatives: how have they worked?
    Shulman SR; Brown JS
    Food Drug Law J; 1995; 50(4):503-31. PubMed ID: 10343017
    [No Abstract]   [Full Text] [Related]  

  • 24. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA.
    Heemstra HE; Leufkens HG; Rodgers RP; Xu K; Voordouw BC; Braun MM
    Drug Discov Today; 2011 Jan; 16(1-2):73-80. PubMed ID: 21094692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Weight of a Term: "Substantial Evidence" and Buried Data.
    Justman S
    Perspect Biol Med; 2018; 61(2):201-214. PubMed ID: 30146519
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A US Food and Drug Administration perspective on evaluating medical products for Ebola.
    Russek-Cohen E; Rubin D; Price D; Sun W; Cox E; Borio L
    Clin Trials; 2016 Feb; 13(1):105-9. PubMed ID: 26768565
    [No Abstract]   [Full Text] [Related]  

  • 27. FDA under pressure to relax drug rules.
    Ledford H
    Nature; 2012 Dec; 492(7427):19. PubMed ID: 23222585
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacogenomic data: FDA voluntary and required submission guidance.
    Salerno RA; Lesko LJ
    Pharmacogenomics; 2004 Jul; 5(5):503-5. PubMed ID: 15212586
    [No Abstract]   [Full Text] [Related]  

  • 29. Science and regulatory rituals associated with the drug development process.
    Versteegh LR
    Food Drug Law J; 1997; 52(2):155-61. PubMed ID: 10557552
    [No Abstract]   [Full Text] [Related]  

  • 30. Regulatory watch: Why do oncology drugs fail to gain US regulatory approval?
    Khozin S; Liu K; Jarow JP; Pazdur R
    Nat Rev Drug Discov; 2015 Jul; 14(7):450-1. PubMed ID: 26000722
    [No Abstract]   [Full Text] [Related]  

  • 31. Oncology 2020: a drug development and approval paradigm.
    Dhingra K
    Ann Oncol; 2015 Nov; 26(11):2347-50. PubMed ID: 26374285
    [No Abstract]   [Full Text] [Related]  

  • 32. Accelerated approval of oncology products: the food and drug administration experience.
    Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
    J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Finding value in the U.S. Food and Drug Administration's Fast Track program.
    Reichert JM; Rochon SL; Zhang BD
    Drug News Perspect; 2009; 22(1):53-8. PubMed ID: 19209299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Accelerated approval of oncology drugs: can we do better?
    Ellenberg SS
    J Natl Cancer Inst; 2011 Apr; 103(8):616-7. PubMed ID: 21422401
    [No Abstract]   [Full Text] [Related]  

  • 35. Food and drug administration expanded access to treatment: implications for oncology patients.
    Freedman RS; Markman M
    Cancer; 2007 Jun; 109(11):2157-60. PubMed ID: 17450587
    [No Abstract]   [Full Text] [Related]  

  • 36. Accelerated approval and oncology drug development timelines.
    Lanthier ML; Sridhara R; Johnson JR; Farrell A; Keegan P; Justice R; Pazdur R
    J Clin Oncol; 2010 May; 28(14):e226-7; author reply e228. PubMed ID: 20194846
    [No Abstract]   [Full Text] [Related]  

  • 37. The Food and Drug Administration's use of postmarketing (Phase IV) study requirements: exception to the rule?
    Steenburg C
    Food Drug Law J; 2006; 61(2):295-383. PubMed ID: 16903034
    [No Abstract]   [Full Text] [Related]  

  • 38. While We're at It, Let's Whack the FDA.
    Chabner BA
    Oncologist; 2016 Mar; 21(3):259-60. PubMed ID: 26869585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The future is now: model-based clinical trial design for Alzheimer's disease.
    Romero K; Ito K; Rogers JA; Polhamus D; Qiu R; Stephenson D; Mohs R; Lalonde R; Sinha V; Wang Y; Brown D; Isaac M; Vamvakas S; Hemmings R; Pani L; Bain LJ; Corrigan B; ;
    Clin Pharmacol Ther; 2015 Mar; 97(3):210-4. PubMed ID: 25669145
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FDA treads delicate line between safety and speed.
    Oncology (Williston Park); 1999 Jan; 13(1):16. PubMed ID: 10027195
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.